SS
FPRX

Steve Schonfeld’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Steve Schonfeld’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-54,011
Closed -$919K – 2362
2020
Q4 		$919K Buy
+54,011
New +$677K 0.01% 847
2016
Q2 		– Sell
-10,111
Closed -$411K – 556
2016
Q1 		$411K Buy
+10,111
New +$348K 0.17% 157

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Steve Schonfeld's FPRX Position: Q1 2021 in Review

Steve Schonfeld sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 54,011 shares — an estimated $919K sold.

Steve Schonfeld first reported a position in FPRX in Q1 2016 and held it in 2 quarters. The position peaked at $919K in Q4 2020. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

  • Steve Schonfeld reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Steve Schonfeld sold 54,011 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $919K.
  • Steve Schonfeld first reported a position in Five Prime Therapeutics, Inc. in Q1 2016 and held it in 2 quarters.
  • Steve Schonfeld's Five Prime Therapeutics, Inc. position peaked at $919K in Q4 2020.
  • 147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2021, filed 17 May 2021.